Stock News

The 2027 rollout will connect Onclarity home collection with Quest's clinician, health-plan and consumer channels.

The Asian program has approximately US$34 million in purchase orders; the Oct. 20 release gives no delivery or revenue timetable for the new order.

The non-exclusive Stevens agreement covers gel and spray formats, but Kane's announcement gives no minimum orders, pricing or revenue forecast.

Miata says four connecting holes establish a 1.5-kilometre mineralized corridor between Jons Trend and Big Berg.

The proposed fund would combine three option tranches with fixed-income investments, while its management fee remains blank.

The Oct. 20 announcement says the process frees capacity for other biosimilars but gives no implementation date or quantified unit-cost savings.

The Nevada permit amendment and reclamation bond are approved, while a dated drilling start and program budget remain unverified.

Escondida, Spence and Copper South Australia produced less copper, while BHP retained its annual forecast of 1.65 million to 1.8 million tonnes.

The timetable calls for a signed grant agreement by March 23, 2027, while the project still needs final investment decisions.

Expansion Zone drilling targets growth beyond the preliminary mine plan; only part of the exploration results is expected to enter the feasibility study.

The province estimates illegal retailers take 30 per cent of cannabis sales and proposes inspection, seizure and penalty powers for the AGCO.

The Ontario infill interval has an estimated true width of 75.7 metres, while the hole ended in mineralization beyond the current pit limit.

Intel, Micron and Sandisk advanced, while Micron's latest quarterly results showed higher cloud-memory and data-centre revenue.

The 1,223 BTC purchase takes holdings to 36,818, while warrant exercises and a pending preferred offering reshape the capital base.

The 183-patient APOLLO study met both primary endpoints, with an FDA resubmission planned by the end of 2026.

The infill assays will inform an updated resource and feasibility study for the Premier mill restart in British Columbia.

The provisional funding would support research components and regular progress reports; the company gave no final approval date.

The bid offers US$1 in cash plus 0.4013 Curaleaf shares for each Aurora share, with a Dec. 4 tender deadline.

An unnamed customer is due to deploy 3 MW on Nov. 1, with initial monthly bills split between US$750,000 in service fees and power charges.

The financially settled COMEX contract would track a Fastmarkets APT assessment for Rotterdam and Baltimore.

Half of induction responders were in remission at one year in the uncontrolled Phase 3 study; Lilly plans global regulatory submissions.

The four businesses generated 36.57 per cent of first-half net profit before intercompany eliminations, and consideration would arrive in instalments.

The first stage requires US$1.25 million in spending and payments over six months to lift its interest to 30 per cent.

The miner kept annual production guidance unchanged as Sierra Gorda paid a US$153 million distribution to South32.

The uncontrolled Phase 2 analysis used a September 2025 cutoff; Zentalis will present the survival data at ESMO on Oct. 23.

The mine produced 39 ounces in September and forecasts about 500 ounces in December as equipment and processing changes take effect.

The once-daily device adds a second ZILBRYSQ self-injection format for adults with anti-AChR-positive gMG, with availability expected in the first quarter of 2027.

Pure holdings remained at zero in the Oct. 16 snapshot, but the weekly post disclosed neither sale prices nor dollar proceeds.

An Oct. 15 filing puts the appointment's effective date at Oct. 14 and details cash and equity terms for the new finance chief.

Exiro Nickel takes over operations while Vale Base Metals retains 18.9 per cent and a multi-year concentrate offtake agreement.

The nonprescription apraclonidine drops are approved for people aged 12 and older, with a U.S. retail launch expected in the coming months.

Golden Summit drilling supports a smaller starter pit for a 2027 prefeasibility study; true widths remain undetermined.

Ryzumvi's expanded indication triggers a milestone payment, while U.S. commercial rights belong to Viatris.

The consolidation would cut outstanding shares to about 2.3 million as a Dec. 2 shareholder vote approaches.

Mapping and sampling will cover 17 Golden Scheelite claims; the company disclosed no program budget or assay-reporting date.

The hormone-free IUD remains approved for three years, with an FDA decision on a duration extension expected in the second quarter of 2027.

The automaker will contribute RMB1 billion, while outside investors commit RMB625 million to MHX Technology under conditional subscription agreements.

Uruguay estimates a US$5.7B project cost, while Solaria's filing leaves its funding share and tenant contracts unspecified.

The uranium study estimates US$349.8 million in development capital ahead of a targeted December investment decision.

U.S. enrolment is expected in early 2027, with up to 80 adults testing EB06 against placebo and topline results due late that year.